Connor, Clark & Lunn Investment Management (CC&L)’s Nuvation Bio NUVB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.18M	Buy	1,207,771 +1,015,773	+529%	+$5.66M	0.01%	677
2025 Q4	$1.72M	Buy	+191,998	New	+$1.19M	﹤0.01%	960
2025 Q1	–	Sell	-422,260	Closed	-$1.12M	–	1543
2024 Q4	$1.12M	Buy	422,260 +25,524	+6%	+$65.7K	0.01%	892
2024 Q3	$909K	Buy	396,736 +32,811	+9%	+$100K	﹤0.01%	911
2024 Q2	$1.06M	Sell	363,925 -18,255	-5%	-$55.7K	﹤0.01%	832
2024 Q1	$1.39M	Buy	382,180 +88,477	+30%	+$170K	0.01%	786
2023 Q4	$443K	Buy	293,703 +17,529	+6%	+$22.6K	﹤0.01%	1075
2023 Q3	$370K	Buy	276,174 +112,891	+69%	+$188K	﹤0.01%	1093
2023 Q2	$294K	Buy	163,283 +107,238	+191%	+$182K	﹤0.01%	1111
2023 Q1	$93K	Sell	56,045 -10,669	-16%	-$21.6K	﹤0.01%	1159
2022 Q4	$128K	Buy	+66,714	New	+$135K	﹤0.01%	1096

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s NUVB Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Nuvation Bio (NUVB) stake by 529% in Q1 2026, buying an estimated $5.66M and bringing the position to 1,207,771 shares worth $5.18M. The position accounts for 0.01% of the portfolio, ranked #677.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in NUVB in Q4 2022 and has held it in 11 quarters since. 233 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 1,207,771 shares of Nuvation Bio worth $5.18M as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 1,015,773 Nuvation Bio shares in Q1 2026, an estimated $5.66M.
Nuvation Bio made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #677 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Nuvation Bio in Q4 2022 and has held it in 11 quarters since.
233 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.